<DOC>
	<DOCNO>NCT00874354</DOCNO>
	<brief_summary>This research do currently effective way regenerate replace heart muscle damage heart attack . The purpose study test whether inject cell obtain patient 's bone marrow coronary artery regenerate replace heart tissue strengthen heart prevent heart dilate develop heart failure .</brief_summary>
	<brief_title>Randomized Evaluation Intracoronary Transplantation Bone Marrow Stem Cells Myocardial Infarction</brief_title>
	<detailed_description>The main objective study investigate safety clinical outcome intracoronary infusion autologous bone marrow cell patient myocardial infarction ( MI ) . We hypothesize patient treated stem cell therapy beneficial effect leave ventricular ( LV ) remodel functional regeneration MI successful primary percutaneous coronary intervention ( PCI ) set prospective randomize controlled trial . Congestive heart failure ( CHF ) , commonly cause acute myocardial infarction ( AMI ) , frequent cause hospitalization United States patient age 65 . Although current pharmacotherapy inhibit neurohormonal activation , fall short prevent LV remodel development CHF . Stem cell undifferentiated pluripotent cell obtain patient potential proliferate differentiation cardiomyocytes . The majority data stem cell transplantation come preclinical animal study . Although result interest perhaps safe , early phase I clinical study small preliminary . Data large , randomize control trial need clarify short long term effect cellular cardiomyoplasty .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients acute myocardial infarction ( ST elevation least 2 lead ≥ 0.2 mV V1 , V2 V3 ≥ 0.1 mV lead ) , treat one follow procedure : Acute PCI stent implantation acute ST elevation MI either denovo lesion instent thrombosis Treatment thrombolysis follow PCI stent implantation . Acute PCI / stent implantation successful ( residual stenosis visually &lt; 30 % TIMI flow ≥ 2 ) . At time inclusion ( ≥ 1 day post PCI ) patient longer require i.v . catecholamine mechanical hemodynamic support ( aortic balloon pump ) Significant regional wall motion abnormality echocardiography time acute PCI ( ejection fraction ≤ 50 % visual estimation ) . Maximal cardiac troponin elevation ≥ 4 ( measure 37° C ) Age 18 80 Years Written inform consent Regional wall motion abnormality outside area involve index acute myocardial infarction . Need acutely revascularize additional vessel , outside infarct artery . Arteriovenous malformation aneurysms Active infection fever diarrhea within last 4 week . Chronic inflammatory disease HIV infection active hepatitis Neoplastic disease without documented remission within past 5 year . Cerebrovascular insult within 3 month Impaired renal function ( creatinine &gt; 2 mg/dl ) time cell therapy Significant liver disease ( GOT &gt; 2x upper limit ) spontaneous INR &gt; 1.5 ) Anemia ( hemoglobin &lt; 8.5 g/dl ) Platelet count &lt; 100,000/µl Hypersplenism History bleed disorder Gastrointestinal bleeding within 3 month Major surgical procedure trauma within 2 month Uncontrolled hypertension Pregnancy Mental retardation Previously perform stem / mononuclear cell therapy Participation another clinical trial within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>Infarct</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Bone Marrow Derived Mononuclear Cells</keyword>
	<keyword>CHF</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Stent</keyword>
	<keyword>PCI</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>